James Rubenstein is an Oncology physician. ClinicalTrials.gov lists 8 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
400 Parnassus Ave
San Francisco, CA 941432202
Telephone
415-353-2421Registry record last updated 11 Sept 2025.
Clinical trials
- Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
Sponsor: James Rubenstein
- Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma
Sponsor: James Rubenstein
- Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
Sponsor: James Rubenstein
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20251 payment
- Genmab U.S., Inc.Program year20241 payment
- ABBVIE INC.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
49.3%Thalidomide Analog32.3%Revlimid50%Pomalyst29%Lenalidomide21%Part D<11 patientsKinase inhibitor17%Imbruvica87%Brukinsa13%Part D<11 patientsDermatology
17.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor17.2%Acyclovir100%Part D≥25 patientsAnti-infectives
16.2%Short-acting sulfonamides8.8%Sulfamethoxazole-Trimethoprim100%Part D≥11 patientsTriazole and tetrazole derivatives3.9%Cresemba100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 2004–2023 per NIH RePORTER. The latest:
- Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NF-kB Activation and Response in Primary CNS Lymphoma
University of California, San Francisco
FY2023$571,523R01CA239462 - Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NF-kB Activation and Response in Primary CNS Lymphoma
University of California, San Francisco
FY2022$584,054R01CA239462 - Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NF-kB Activation and Response in Primary CNS Lymphoma
University of California, San Francisco
FY2021$613,413R01CA239462
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”